(0.32%) 5 116.47 points
(0.32%) 38 361 points
(0.36%) 15 985 points
(-0.86%) $83.13
(5.93%) $2.04
(0.37%) $2 355.90
(0.47%) $27.67
(4.02%) $959.15
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.29%
@ $3.97
発行日: 14 2月 2024 @ 23:30
リターン: -41.06%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 1.28 %
Live Chart Being Loaded With Signals
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation...
Stats | |
---|---|
本日の出来高 | 92 895.00 |
平均出来高 | 425 764 |
時価総額 | 129.06M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.400 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.300 |
ATR14 | $0.00800 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-07 | Mccauley Thomas | Buy | 125 000 | Stock Option (Right to Buy) |
2024-02-07 | Mccauley Thomas | Buy | 75 000 | Stock Option (Right to Buy) |
2024-02-07 | Karande Mahesh | Buy | 314 326 | Stock Option (Right to Buy) |
2024-02-07 | Karande Mahesh | Buy | 209 551 | Stock Option (Right to Buy) |
2024-02-07 | Moore Yan | Buy | 110 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.71 |
Last 90 transactions |
Buy: 34 429 434 | Sell: 15 655 033 |
ボリューム 相関
Omega Therapeutics, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Omega Therapeutics, Inc. 相関 - 通貨/商品
Omega Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $3.09M |
総利益: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2023 |
収益: | $3.09M |
総利益: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2022 |
収益: | $2.07M |
総利益: | $-3.12M (-150.36 %) |
EPS: | $-2.14 |
FY | 2021 |
収益: | $144 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。